PMID- 35545143
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20230124
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 364
IP  - 4
DP  - 2022 Oct
TI  - Synthetic cannabinoids and ST elevation myocardial infarction.
PG  - 481-491
LID - S0002-9629(22)00215-4 [pii]
LID - 10.1016/j.amjms.2022.05.001 [doi]
AB  - Synthetic cannabinoids cannot be detected on a standard urine drug screen (UDS), 
      making them a convenient drug of abuse. We report the first case of ST elevation 
      myocardial infarction (STEMI) in a young patient due to coronary artery 
      thrombosis secondary to synthetic cannabinoid use and concurrent COVID-19 
      infection. A 38-year-old previously healthy male developed severe chest pain and 
      was found to have anterior STEMI and COVID-19 infection. Coronary angiography 
      showed acute thrombotic occlusion of the mid-left anterior descending artery that 
      was managed with thrombectomy and stent placement. He only required supportive 
      care for COVID-19. A comprehensive literature search revealed 34 additional cases 
      of STEMI with synthetic cannabinoid use; majority were males (97%) with mean age 
      of 29 years. 29 patients (85.3%) underwent coronary angiography and majority had 
      left anterior descending artery (LAD) involvement (55%), with 13 (44.8%) 
      undergoing stent placement. We highlight STEMI as a potentially lethal 
      complication of synthetic cannabinoids; prompt angiography may be lifesaving.
CI  - Copyright (c) 2022 Southern Society for Clinical Investigation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Jafry, Ali Haider
AU  - Jafry AH
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States. Electronic address: ali-jafry@ouhsc.edu.
FAU - LaGrow, Austin
AU  - LaGrow A
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
FAU - Akhtar, Khawaja Hassan
AU  - Akhtar KH
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
FAU - Hacker, Ethan
AU  - Hacker E
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
FAU - Russell, Sage
AU  - Russell S
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
FAU - Kliewer, Brian
AU  - Kliewer B
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
FAU - Asad, Zain Ul Abideen
AU  - Asad ZUA
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma, United States.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20220508
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Cannabinoids)
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - *Cannabinoids/adverse effects
MH  - Coronary Angiography
MH  - *Coronary Thrombosis/complications
MH  - Female
MH  - Humans
MH  - Male
MH  - *ST Elevation Myocardial Infarction/diagnostic imaging/etiology/surgery
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - COVID-19
OT  - K2
OT  - Spice
OT  - Synthetic cannabinoids
COIS- Declaration of Competing Interest None declared.
EDAT- 2022/05/12 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/05/11 19:23
PHST- 2021/10/07 00:00 [received]
PHST- 2022/03/16 00:00 [revised]
PHST- 2022/05/02 00:00 [accepted]
PHST- 2022/05/12 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/05/11 19:23 [entrez]
AID - S0002-9629(22)00215-4 [pii]
AID - 10.1016/j.amjms.2022.05.001 [doi]
PST - ppublish
SO  - Am J Med Sci. 2022 Oct;364(4):481-491. doi: 10.1016/j.amjms.2022.05.001. Epub 
      2022 May 8.